Hosted by ShareVault
- Jeffrey Bockman, PhD, EVP, BioConsulting, Head of Oncology, Lumanity
- Lisa Butterfield, VP, R&D, Adjunct Professor at Parker Institute for Cancer Immunotherapy/UCSF
The search for a cancer vaccine has been ongoing for decades, going back to the days when Immuno-Oncology was known as Tumor Immunology. And progress has been made on several fronts, from identifying target/antigens like neoantigens, adjuvants, Oncolytic Viruses, and immunization platforms like peptides, to lab development of genetic vaccine tools, like messenger ribonucleic acid (mRNA). In the past decade, researchers have identified checkpoint inhibitors, those points in the immune system that discriminate between healthy and foreign cells, and from that knowledge scientists have unlocked secrets of the immunosuppressive tumor microenvironment (TME) to discover how immune cells see and react to antigens.
However, progress in the lab and development of vaccine experimental models have generated only modest progress in clinical trials, where proof of concept is translated into real-life patient benefit. To date, there is only one approved cancer vaccine, Provenge, which was approved more than a decade ago.
The question remains: Why has the field not progressed as fast and as far as many insiders might have hoped? Why have the positive responses in animal models not been able to be replicated in human trials?
For an inside look at the promise and challenges of a cancer vaccine, join us for, “The Travails and Promise of Cancer Vaccines,” with two of the leading experts in the field. This webinar provides an overview of the field, including the strategic, financing, and partnering components of vaccine development, and an in-depth look at how researchers, oncologists, and Life Science companies can overcome stumbling blocks and see cancer vaccines realize their true potential.